TMLB-C16

TMLB-C16 is a potent and orally active B3GAT3 inhibitor with a KD of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC50 = 6.53 μM) and HCCLM3 cells (IC50 = 6.22 μM) . TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research[1].

Product Specifications

CAS Number

[2923531-50-2]

UNSPSC

12352005

Target

Apoptosis; Caspase; CDK; PARP

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(C1=CC2=C(NC=C2C(C(NC3C(N(CC3)C4=CC=C(C)C=C4Cl)=O)=O)=O)C=C1)OC

Molecular Formula

C23H20ClN3O5

Molecular Weight

453.88

References & Citations

[1]Yin H, et al. Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. J Med Chem. 2024 Jul 11;67 (13) :10743-10773.